Realcan Pharmaceutical Group Co Ltd
SZSE:002589
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
EV/EBITDA
Enterprise Value to EBITDA (EV/EBITDA) ratio compares a company`s total enterprise value to its earnings before interest, taxes, depreciation, and amortization. It shows how much investors are paying for each dollar of the company`s earnings, including both equity and debt.
Enterprise Value to EBITDA (EV/EBITDA) ratio compares a company`s total enterprise value to its earnings before interest, taxes, depreciation, and amortization. It shows how much investors are paying for each dollar of the company`s earnings, including both equity and debt.
Valuation Scenarios
If EV/EBITDA returns to its Industry Average (26.2), the stock would be worth ¥-0.51 (116% downside from current price).
| Scenario | EV/EBITDA Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | -167.4 | ¥3.24 |
0%
|
| Industry Average | 26.2 | ¥-0.51 |
-116%
|
| Country Average | 28.8 | ¥-0.56 |
-117%
|
Forward EV/EBITDA
Today’s price vs future ebitda
Peer Comparison
| Market Cap | EV/EBITDA | P/E | ||||
|---|---|---|---|---|---|---|
| CN |
|
Realcan Pharmaceutical Group Co Ltd
SZSE:002589
|
4.9B CNY | -167.4 | -806.1 | |
| US |
|
Mckesson Corp
NYSE:MCK
|
101.9B USD | 16.5 | 23.5 | |
| US |
|
Cencora Inc
NYSE:COR
|
59.9B USD | 13.1 | 36.9 | |
| US |
A
|
Amerisourcebergen Corp
LSE:0HF3
|
59.4B USD | 13 | 36.6 | |
| US |
|
Cardinal Health Inc
NYSE:CAH
|
47.2B USD | 13.8 | 28.4 | |
| AU |
|
Sigma Healthcare Ltd
ASX:SIG
|
32.1B AUD | 26.2 | 35.3 | |
| CN |
|
Shanghai Pharmaceuticals Holding Co Ltd
SSE:601607
|
62.9B CNY | 8.6 | 11 | |
| US |
|
Henry Schein Inc
NASDAQ:HSIC
|
9B USD | 11.1 | 22.6 | |
| CN |
|
Huadong Medicine Co Ltd
SZSE:000963
|
59.8B CNY | 12.5 | 16.2 | |
| KR |
|
Celltrion Healthcare Co Ltd
KOSDAQ:091990
|
12.2T KRW | 59.9 | 89.6 | |
| CN |
|
Sinopharm Group Co Ltd
HKEX:1099
|
61B HKD | 0.5 | 7.6 |
Market Distribution
| Min | 0 |
| 30th Percentile | 16.3 |
| Median | 28.8 |
| 70th Percentile | 53.1 |
| Max | 49 021 |
Other Multiples
Realcan Pharmaceutical Group Co Ltd
Glance View
Realcan Pharmaceutical Group Co., Ltd.. engages in the provision of medical services. The company is headquartered in Yantai, Shandong and currently employs 8,369 full-time employees. The company went IPO on 2011-06-10. The firm operates its businesses through three segments. The Medical segment is engaged in the provision of Chinese medicine materials, Chinese medicine tablets, Chinese patent medicines, chemical drug materials, chemical preparations, antibiotics, biochemical pharmaceuticals, biological products, psychotropic substances, anesthetic medicines and peptide hormones. The Equipment is engaged in the provision of medical equipment. The Mobile Medical segment is engaged in the provision of medical and logistics services and mobile medical information services. The firm conducts its businesses mainly within domestic markets, with Shandong as its main market.
